Plasma Metabolic and Inflammatory Protein Signatures in Psychiatric Disorders.

Area of Science:

• Biochemistry
• Psychiatry
• Proteomics
• Metabolomics

Background:

• Schizophrenia (SCZ), bipolar disorder (BD), and schizoaffective disorder (SAD) are challenging to diagnose using current clinical methods.
• Limitations in diagnosis lead to under-diagnosis and treatment delays for severe psychiatric disorders.
• There is a need for objective biomarkers to improve diagnostic accuracy and treatment strategies.

Purpose of the Study:

• To identify molecular patterns in plasma using metabolomic and proteomic approaches.
• To differentiate patients with SCZ, BD, and SAD from healthy controls.
• To enhance understanding of the pathophysiology of these psychiatric disorders.

Main Methods:

• Mass spectrometry-based metabolomic profiling of plasma samples.
• Targeted analysis of inflammatory proteins in patient and control groups.
• Unsupervised analysis to identify distinct molecular profiles.
• Inclusion of 26 BD, 34 SCZ, 16 SAD patients, and age/sex-matched controls (DSM-5 criteria).

Main Results:

• Clear separation observed between patients and controls, indicating distinct metabolic and inflammatory profiles.
• No significant differentiation among the three psychiatric disorder subgroups (BD, SCZ, SAD).
• Key differentiating biomolecules include decreased proinflammatory cytokines, amino acids, glycerophospholipids, and increased acylcarnitines.

Conclusions:

• Metabolomic and proteomic profiling can distinguish patients with severe psychiatric disorders from controls.
• Shared biological profiles exist across SCZ, BD, and SAD.
• Omics approaches offer potential for refining diagnosis and treatment of psychiatric disorders beyond clinical symptoms.